文献速递白血病淋巴瘤

Duvelisib 治疗与凋亡调节因子表达改变相关并帮助增敏慢性淋巴细胞白血病细胞对 Venetoclax(ABT-199)的敏感性

Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199).
PubMed 文献 · Leukemia · 2016-12-26

Duvelisib 是口服 PI3K-δ 和 PI3K-γ 双重抑制剂,在慢性淋巴细胞白血病(CLL)中单药治疗有较高 iwCLL 和淋巴结缓解率但完全缓解罕见。研究对 duvelisib I 期试验中 CLL 患者样本进行基因表达和蛋白检测,发现 BCL2 及多个 BH3-only 促凋亡基因表达增加,且 duvelisib 治疗后 CLL 细胞对 venetoclax 诱导的凋亡更敏感。体外联合 duvelisib 与 venetoclax 在模拟肿瘤微环境条件下仍增强凋亡。

要点

  • Duvelisib 治疗上调 CLL 细胞 BCL2 及 BH3-only 促凋亡基因的转录和蛋白表达。
  • Duvelisib 治疗后患者 CLL 细胞对 venetoclax 诱导的凋亡较治疗前更敏感。
  • 体外 duvelisib 联合 venetoclax 在模拟肿瘤微环境条件下仍增强凋亡。

核心结论

  • Duvelisib 治疗与凋亡调节因子表达改变相关,为 duvelisib 联合 venetoclax 在临床中测试提供了机制依据。

研究设计与样本

  • 研究获取 duvelisib I 期试验中 CLL 患者的样本,采用 RNAseq、Nanostring、Affymetrix 芯片和实时 RT-PCR 进行基因表达研究,并用反向蛋白芯片和免疫印迹确认蛋白水平。

主要发现

  • 基因表达研究显示 BCL2 及多个 BH3-only 促凋亡基因表达增加,反向蛋白芯片和免疫印迹证实蛋白水平升高。
  • Venetoclax 在离体培养的 duvelisib 治疗后患者 CLL 细胞中诱导的凋亡大于同一患者治疗前 CLL 细胞。
  • 体外联合 duvelisib 与 venetoclax 在模拟肿瘤微环境的培养条件下仍增强凋亡。

关键数值与推荐

  • Duvelisib 单药在 CLL 中与高 iwCLL 和淋巴结缓解率相关,但完全缓解罕见。

临床怎么用

  • 作者认为这些数据为在临床中测试 duvelisib 联合 venetoclax 提供了机制依据。
  • 该联合方案(NCT02640833)正在 B 细胞恶性肿瘤包括 CLL 患者中评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Duvelisib, an oral dual inhibitor of PI3K-δ and PI3K-γ, is in phase III trials for the treatment of chronic lymphocytic leukemia (CLL) and indolent non-Hodgkin's lymphoma. In CLL, duvelisib monotherapy is associated with high iwCLL (International Workshop on Chronic Lymphocytic Leukemia) and nodal response rates, but complete remissions are rare. To characterize the molecular effect of duvelisib, we obtained samples from CLL patients on the duvelisib phase I trial. Gene expression studies (RNAseq, Nanostring, Affymetrix array and real-time RT-PCR) demonstrated increased expression of BCL2 along with several BH3-only pro-apoptotic genes. In concert with induction of transcript levels, reverse phase protein arrays and immunoblots confirmed increase at the protein level. The BCL2 inhibitor venetoclax induced greater apoptosis in ex vivo-cultured CLL cells obtained from patients on duvelisib compared with pre-treatment CLL cells from the same patients. In vitro combination of duvelisib and venetoclax resulted in enhanced apoptosis even in CLL cells cultured under conditions that simulate the tumor microenvironment. These data provide a mechanistic rationale for testing the combination of duvelisib and venetoclax in the clinic. Such combination regimen (NCT02640833) is being evaluated for patients with B-cell malignancies including CLL.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Patel VM, Balakrishnan K, Douglas M, et al. Duvelisib treatment is associated with altered expression of apoptotic regulators that helps in sensitization of chronic lymphocytic leukemia cells to venetoclax (ABT-199). Leukemia. 2016. PMID: 28017967. doi:10.1038/leu.2016.382

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。